Goodness Growth Holdings, Inc. a physician-led, science-focused cannabis company and IP developer, today announced that its subsidiary, Vireo of Charm City, LLC, has successfully completed the previously-disclosed purchase of all substantial assets of Charm City Medicus, LLC, a medical cannabis dispensary located in Baltimore, Maryland . The transaction was finalized on November 19, 2021 . The transaction was ...

- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP developer, today announced that its subsidiary, Vireo of Charm City, LLC, has successfully completed the previously-disclosed purchase of all substantial assets of Charm City Medicus, LLC, a medical cannabis dispensary located in Baltimore, Maryland . The transaction was finalized on November 19, 2021 .

The transaction was completed after the Maryland Medical Cannabis Commission granted final approval of the transfer of the medical cannabis dispensary license. The dispensary will be rebranded to Green Goods Baltimore to align the location with the Company's national retail dispensary brand, Green Goods®. Goodness Growth now operates 18 dispensaries across the country.

"We have been looking forward to closing this transaction and growing our retail market share in Maryland's medical cannabis market. We are excited to introduce our Green Goods™ dispensary brand to the Baltimore area," said Chairman and Chief Executive Officer, Kyle Kingsley , M.D. "With our recent new brand launches and initiatives to expand cultivation and processing capacity in Maryland , we're in an excellent position to continue growing our wholesale and retail sales in the state as our manufacturing capabilities enable us to offer the full spectrum of cannabis products to patients."

The total consideration for the transaction at closing was US $8.0 million , including $4.0 million in cash, $2.0 million in Goodness Growth stock, and a $2.0 million promissory note issued to the seller. Goodness Growth shares issued in conjunction with the transaction are subject to a one-year lock-up agreement.

About Goodness Growth Holdings, Inc.

Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world. The Company's operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, Inc., and its science and intellectual property incubator, Resurgent Biosciences, Inc. The Company manufactures proprietary, branded cannabis products in environmentally friendly facilities and state-of-the-art cultivation sites and distributes its products through its growing network of Green Goods ® and other retail locations and third-party dispensaries. Its team of more than 500 employees are focused on the development of differentiated products, driving scientific innovation of plant-based medicines, and developing meaningful intellectual property. Today, the Company is licensed to grow, process, and/or distribute cannabis in eight markets and operates 18 dispensaries across the United States . For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com .

Contact Information

Investor Inquiries:

Media Inquiries:

Sam Gibbons

Albe Zakes

Vice President, Investor Relations

Vice President, Corporate Communications

samgibbons@vireohealth.com

albezakes@vireohealth.com

(612) 314-8995

(267) 221-4800

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/goodness-growth-holdings-announces-closing-of-purchase-of-charm-city-medicus-dispensary-in-baltimore-maryland-301429349.html

SOURCE Goodness Growth Holdings, Inc.

News Provided by PR Newswire via QuoteMedia

BevCanna Announces Strong Third Quarter 2021 Financial Results

BevCanna Announces Strong Third Quarter 2021 Financial Results

Increases revenues by more than 1000 per cent over the comparable quarter of 2020

BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) ("BevCanna" or the "Company"), an emerging leader in innovative health and wellness beverages and products, today reported its unaudited financial results for the quarter ended September 30, 2021.

Keep reading... Show less
Numinus to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

Numinus to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 2 nd Annual Psychedelics Conference to be hosted virtually on Monday, December 6, 2021 .

Payton Nyquvest , Founder and CEO of Numinus, will participate in the Psychedelics Assisted Psychotherapy panel at 1:30 p.m. ET . In addition, a corporate presentation by Mr. Nyquvest will be available on-demand. To attend, register here .

Keep reading... Show less

Fab 5 Freddy and Curaleaf Expand B NOBLE Cannabis Brand to New York Medical Market

Now in Ten States, B NOBLE Partnership Advances Social Equity in Cannabis and Provides Opportunity to Those Directly Impacted by the War on Drugs

B NOBLE Inc. and Curaleaf, a leading international provider of consumer products in cannabis, today announced the expansion of its B NOBLE partnership into medical dispensary locations in New York . This expansion is one of the first partnerships of its kind in New York as the New York Cannabis Control Board recently approved whole flower as part of its medical marijuana offerings in late October.

Keep reading... Show less
Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina

Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina

Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has entered into a partnership with an established Argentine pharmaceutical company to register and commercialize Avicanna's proprietary cannabinoid-based pharmaceutical preparations through the licensing of its intellectual property and supply of its active pharmaceutical ingredients ("API").

Through the partnership Avicanna will provide a non-exclusive license of the Company's intellectual property related to its proprietary 10% cannabidiol ("CBD") pharmaceutical drug preparation. Additionally, the partner will source its pharmaceutical-grade CBD exclusively from Avicanna to manufacture the product for the registration and marketing authorization with the Argentine regulatory agency ANMAT.

Keep reading... Show less
Tinley's Announces Q3 2021 Results and Provides Corporate Updates

Tinley's Announces Q3 2021 Results and Provides Corporate Updates

The Tinley Beverage Company Inc. (CSE:TNY; OTC:TNYBF) ("Tinley's" or the "Company") is pleased to provide corporate updates to coincide with the release today of the Company's condensed interim consolidated financial statements and management's discussion and analysis thereon for the three and nine months ended September 30, 2021, which are accessible under the Company's profile on SEDAR at www.sedar.com .

Third Quarter 2021 Financial Highlights

Keep reading... Show less

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Cronos Group Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofCronos Group Inc. ("Cronos" or "the Company") (NASDAQ:CRON) for violations of the securities laws

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cronos filed a Form 8-K with the SEC on November 9, 2021, disclosing that the Company would "be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021" and that "the Company's financial statements for this period should therefore no longer be relied upon." Based on this news, shares of Cronos fell by nearly 16%.

Keep reading... Show less

Top News

Related News